Anthony J. Tang
Research Subjects
Anthony J. Tang has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Jeffrey N. Bruce
Department of Neurological Surgery, Columbia University Irving Medical Center/NY- Presbyterian Hospital, 710 W 168th Street, Room 434, New York, NY, 10032, USA
3 shared publicationsPeter Canoll
Department of Pathology and Cell Biology, Columbia University Irving Medical Center/NY-Presbyterian Hospital, 630 W 168th Street, New York, NY, 10032, USA
3 shared publicationsAlan X. Chen
Department of Neurological Surgery, Columbia University Irving Medical Center/NY- Presbyterian Hospital, 710 W 168th Street, Room 434, New York, NY, 10032, USA
2 shared publicationsAlex H. Manriquez
Department of Neurological Surgery, Columbia University Irving Medical Center/NY- Presbyterian Hospital, 710 W 168th Street, Room 434, New York, NY, 10032, USA
2 shared publicationsArjun R. Adapa
Department of Neurological Surgery, Columbia University Irving Medical Center/NY- Presbyterian Hospital, 710 W 168th Street, Room 434, New York, NY, 10032, USA
2 shared publicationsAshwin Viswanathan
Department of Neurological Surgery, Columbia University Irving Medical Center/NY- Presbyterian Hospital, 710 W 168th Street, Room 434, New York, NY, 10032, USA
2 shared publications
Latest Publications
- 8 May 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 177 (3)
cGAS-STING agonists in preclinical glioblastoma animal models: a systematic review of tumor microenvironment modulation and survival outcomes
Glioblastoma (GBM) is characterized by an immunosuppressive tumor microenvironment and poor responsiveness to immune checkpoint blockade, driving interest in cGAS-STING pathway activation to stimulate antitumor immunity. We performed a systematic review of preclinical in vivo studies evaluating STING agonists in glioblastoma, with emphasis on immune microenvironment effects and survival outcomes. A systematic review of PubMed, Cochrane, and Embase was conducted through February 2025 following PRISMA guidelines. Studies were included if they evaluated STING agonists in live animal models of GBM and reported survival outcomes or tumor microenvironment changes. Two reviewers independently screened studies and extracted data. Risk of bias was assessed qualitatively based on study design and reporting characteristics. Given heterogeneity in models, treatments, and outcomes, results were synthesized descriptively. Fourteen studies met the inclusion criteria, spanning synthetic and natural cyclic dinucleotides and non-cyclic STING agonists. Across diverse delivery methods, including intracranial injection, hydrogels, and nanoparticle systems, STING agonists were associated with increased CD8 + T-cell and NK cell infiltration and repolarization of tumor-associated macrophages toward pro-inflammatory phenotypes. Several studies reported prolonged survival, including long-term tumor clearance in select models. Combination therapies with immune checkpoint inhibitors or radiotherapy showed synergistic effects in some studies. STING agonists can enhance anti-tumor immune responses and prolong survival in preclinical GBM models by promoting cytotoxic lymphocyte recruitment and remodeling the tumor-associated myeloid landscape. However, translation remains challenging due to limitations of current models, the limited clinical traction STING modulation has thus far achieved in other cancer types, incomplete understanding of cell-type-specific STING activation in the brain, and the possibility that sustained STING signaling may drive maladaptive inflammation rather than durable antitumor immunity.
- 8 May 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 177 (3)
cGAS-STING agonists in preclinical glioblastoma animal models: a systematic review of tumor microenvironment modulation and survival outcomes
Glioblastoma (GBM) is characterized by an immunosuppressive tumor microenvironment and poor responsiveness to immune checkpoint blockade, driving interest in cGAS-STING pathway activation to stimulate antitumor immunity. We performed a systematic review of preclinical in vivo studies evaluating STING agonists in glioblastoma, with emphasis on immune microenvironment effects and survival outcomes. A systematic review of PubMed, Cochrane, and Embase was conducted through February 2025 following PRISMA guidelines. Studies were included if they evaluated STING agonists in live animal models of GBM and reported survival outcomes or tumor microenvironment changes. Two reviewers independently screened studies and extracted data. Risk of bias was assessed qualitatively based on study design and reporting characteristics. Given heterogeneity in models, treatments, and outcomes, results were synthesized descriptively. Fourteen studies met the inclusion criteria, spanning synthetic and natural cyclic dinucleotides and non-cyclic STING agonists. Across diverse delivery methods, including intracranial injection, hydrogels, and nanoparticle systems, STING agonists were associated with increased CD8 + T-cell and NK cell infiltration and repolarization of tumor-associated macrophages toward pro-inflammatory phenotypes. Several studies reported prolonged survival, including long-term tumor clearance in select models. Combination therapies with immune checkpoint inhibitors or radiotherapy showed synergistic effects in some studies. STING agonists can enhance anti-tumor immune responses and prolong survival in preclinical GBM models by promoting cytotoxic lymphocyte recruitment and remodeling the tumor-associated myeloid landscape. However, translation remains challenging due to limitations of current models, the limited clinical traction STING modulation has thus far achieved in other cancer types, incomplete understanding of cell-type-specific STING activation in the brain, and the possibility that sustained STING signaling may drive maladaptive inflammation rather than durable antitumor immunity.
- 14 August 2024
- Published by Elsevier in World Neurosurgery
- Vol. 190, e931-e938
Optimizing Surgical Outcomes for Intracranial Epidermoid Tumors: A Retrospective Analysis of Clinical Predictors, Surgical Decisions, and Patient Clustering
- 14 August 2024
- Published by Elsevier in World Neurosurgery
- Vol. 190, e931-e938
Optimizing Surgical Outcomes for Intracranial Epidermoid Tumors: A Retrospective Analysis of Clinical Predictors, Surgical Decisions, and Patient Clustering
- 1 April 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 11 (4) , 383-394
Biomarkers of immunotherapy in glioblastoma
Glioblastoma (GBM) is the most common primary brain cancer, comprising half of all malignant brain tumors. Patients with GBM have a poor prognosis, with a median survival of 14–15 months. Current therapies for GBM, including chemotherapy, radiotherapy, and surgical resection, remain inadequate. Novel therapies are required to extend patient survival. Although immunotherapy has shown promise in other cancers, including melanoma and non-small lung cancer, its efficacy in GBM has been limited to subsets of patients. Identifying biomarkers of immunotherapy response in GBM could help stratify patients, identify new therapeutic targets, and develop more effective treatments. This article reviews existing and emerging biomarkers of clinical response to immunotherapy in GBM. The scope of this review includes immune checkpoint inhibitor and antitumoral vaccination approaches, summarizing the variety of molecular, cellular, and computational methodologies that have been explored in the setting of anti-GBM immunotherapies.
- 1 April 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 11 (4) , 383-394
Biomarkers of immunotherapy in glioblastoma
Glioblastoma (GBM) is the most common primary brain cancer, comprising half of all malignant brain tumors. Patients with GBM have a poor prognosis, with a median survival of 14–15 months. Current therapies for GBM, including chemotherapy, radiotherapy, and surgical resection, remain inadequate. Novel therapies are required to extend patient survival. Although immunotherapy has shown promise in other cancers, including melanoma and non-small lung cancer, its efficacy in GBM has been limited to subsets of patients. Identifying biomarkers of immunotherapy response in GBM could help stratify patients, identify new therapeutic targets, and develop more effective treatments. This article reviews existing and emerging biomarkers of clinical response to immunotherapy in GBM. The scope of this review includes immune checkpoint inhibitor and antitumoral vaccination approaches, summarizing the variety of molecular, cellular, and computational methodologies that have been explored in the setting of anti-GBM immunotherapies.